Clinical trials: Hematological Malignancy, open to volunteers
Oral Mucositis, Total Body Irradiation
Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to Transplant
The goal of this phase II, single-arm interventional clinical trial is to evaluate whether oral sodium copper chlorophyllin (CHL) can reduce the frequency and severity of oral mucositis in patients aged 12-65 years undergoing…
- Conditions
- Oral Mucositis, Total Body Irradiation, Hematological Malignancies, Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- ChROMME-TBI (NCT07709195)
- Testing
- Sodium Copper Chlorophyllin
- Where
- India
- Volunteers
- 17 people
- Sponsor
- Tata Memorial Centre
Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease
Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients
What is acute Graft versus host disease (aGvHD)? GvHD is a complication that can occur after an allogeneic stem cell transplant resulting in damage to some organs. The death rate of GvHD patients is 15-40%.
- Conditions
- Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease, Hematological Malignancy
- Trial name
- NCT07724873
- Testing
- SWA (standardized root extract of Withania somnifera)
- Where
- 2 sites in India
- Volunteers
- 54 people
- Sponsor
- Tata Memorial Centre
Cancer, Anticancer Treatment
Risk Prediction Scores for Cardiotoxicity in Cancer Patients Treated With Cardiotoxic Anticancer Therapies in Europe
Cancer management has undergone major advances over the past 30 years. Several anticancer therapies are now highly effective, allowing many cancers to become chronic diseases through sequential lines of treatment.
- Conditions
- Cancer, Anticancer Treatment, Cardiovascular Disease Risk Factor, Cardiovascular Diseases
- Trial name
- EUCARTOXSCORES (NCT07621289)
- Testing
- antineoplastic agents, endocrine therapy, immunostimulants drugs (ATC classification)
- Volunteers
- 10,000 people
- Sponsor
- University Hospital, Caen
Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies
To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers
Cyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant.
- Trial name
- NCT07719946
- Testing
- Cyclophosphamide
- Where
- 2 sites in India
- Volunteers
- 20 people
- Sponsor
- Tata Memorial Centre
Hematological Malignancy, GVHD - Graft-Versus-Host Disease
Study of Standardized Withaferin-A for the Treatment of Steroid Refractory Acute Graft Versus Host Disease.
Study Design Prospective, single center, single arm, Phase II study. Research aims and objectives Aim: To evaluate the efficacy and safety of standardized Withaferin A in steroid refractory acute GvHD in patients post allogeneic…
- Conditions
- Hematological Malignancy, GVHD - Graft-Versus-Host Disease, Steriod Refractory
- Trial name
- Withaferin_A (NCT07708987)
- Testing
- Standardized Withaferin A (SWA)
- Where
- India
- Volunteers
- 34 people
- Sponsor
- Tata Memorial Centre
Hematological Malignancies
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies
This is a long-term follow-up study for participants treated with Galapagos (GLPG) CAR T-cell therapies to evaluate the long-term safety and efficacy of GLPG CAR T-cell products for 15 years post infusion.
- Trial name
- Hesperia (NCT06652633)
- Testing
- GLPG CAR T-cell therapy
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 546 people
- Sponsor
- Lakefront Biotherapeutics NV
Hematological Malignancy, Leukemia
Halt Aging in Survivors of Blood Cancers
Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions.
- Conditions
- Hematological Malignancy, Leukemia, Lymphoid Leukemia, Multiple Myeloma
- Trial name
- HALTAging-1 (NCT07292272)
- Testing
- Behavioral Coaching Intervention, Virtual Exercise Platform
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Nebraska
Relapsed and Refractory CD5 Hematological Tumors
CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors
This is an investigator-initiated dose-finding clinical study with the primary objective of evaluating the safety of CD5CART in the treatment of subjects with relapsed and refractory CD5 hematological malignancies and to explore…
- Trial name
- NCT07234110
- Testing
- Fully human CD5 chimeric antigen receptor T cell injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hematological Malignancies B
Biodistribution, Dosimetry, and Safety of 68Ga-EV203 in Hematological Malignancies
The goal of this clinical trial is to evaluate the biodistribution, radiation dosimetry, safety, and time-dependent image quality of ^68^Ga-EV203 injection in patients with hematological malignancies (multiple myeloma…
- Trial name
- NCT07670949
- Testing
- 68Ga-EV203 PET/CT
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Hematological Malignancies
Immunological Impact of a Post Cell Therapy Treatment With FLT3 Inhibitors
Allogeneic hematopoietic stem cell transplantation (aHSCT) is the only curative option for many hematological maligancies. The main cause of death following HSCT is the relapse of the original disease.
- Trial name
- TARGETALLO (NCT06992934)
- Testing
- Gilteritinib
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Hematological Malignancies, Platelet Transfusion Refractoriness (PTR)
Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies
Platelet transfusion refractoriness (PTR) is a common complication in patients with hematological malignancies. It not only prolongs the duration of platelet transfusion dependence and significantly increases the risk of…
- Conditions
- Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies
- Trial name
- AB-HLA-2026 (NCT07635511)
- Testing
- Acalabrutinib maleate, bortezomib, HLA-matched or crossmatched irradiated platelets
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Luspatercept, Epoetin
Luspatercept vs Epoetin in Treating Poor Erythroid Engraftment for Hematological Malignancies
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective therapy for hematological malignancies. Nonetheless, poor graft function remains a life-threatening complication after allo-HSCT.
- Conditions
- Luspatercept, Epoetin, Poor Erythroid Engraftment, Hematological Malignancies
- Trial name
- NCT07636486
- Testing
- Luspatercept, Epoetin
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
Blood cancers occur when the molecules that control normal cell growth are damaged. Many of these changes can be detected by directly examining parts of the cancer or cells in blood.
- Conditions
- Monoclonal Gammopathy of Undetermined Significance (MGUS), Myelodysplastic Syndromes, Hematological Malignancies, B-cell Malignancy, Low-grade
- Trial name
- NCT02269592
- Where
- 7 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Dana-Farber Cancer Institute
Solid Tumors, Hematological Tumor
Romiplostim N01 for Chemotherapy-Induced Thrombocytopenia in Pediatric Cancer Patients
The goal of this clinical trial is to evaluate the efficacy and safety of romiplostim N01 in treating chemotherapy-induced thrombocytopenia (CIT) in children and adolescents/young adults (CAYA; aged 6-24 years) with hematologic…
- Conditions
- Solid Tumors, Hematological Tumor, Children, Adolescent
- Trial name
- NCT07043894
- Testing
- Romiplostim N01
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Childhood Cancer, Hematological Disorders
Fertility in Young Adults Who Did (Not) Store Testicular Tissue Before a Treatment Leading to Fertility Problems
The goal of this prospective comparative interventional cohort study is to assess the fertility status of young adult men (≥18 years) who received gonadotoxic treatment during childhood for the treatment of cancer or…
- Trial name
- NCT04202094
- Testing
- Physical examination, Scrotum ultrasound, Blood sample
- Where
- Belgium
- Volunteers
- 50 people
- Sponsor
- Universitair Ziekenhuis Brussel
Art-based Intervention, Hematological Cancer
The Effect of Art-Based Intervention on Fatigue, Anxiety, Perception of Nurse Presence, and Quality of Life in Patients With Hematological Cancers
This study will be conducted in a randomized controlled experimental design to examine The effect of art-based intervention on fatigue, anxiety, perception of nurse presence, and quality of life in patients with hematological…
- Conditions
- Art-based Intervention, Hematological Cancer, Nurse Presence, Quality of Life
- Trial name
- NCT07551817
- Testing
- art-based intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 52 people
- Sponsor
- Gazi University
Myeloid Malignancy, Genetic Predisposition to Disease
Germline Testing for Predisposition to Myeloid Malignancies
The goal of this research study is to evaluate the feasibility of germline genetic testing using the investigational MyeloGen Gene Panel in adult participants diagnosed with myeloid malignancies.
- Conditions
- Myeloid Malignancy, Genetic Predisposition to Disease, Myeloid Hematological Malignancies
- Trial name
- MyeloGen (NCT07112287)
- Testing
- MyeloGen Gene Panel
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Christopher Reilly
Hematological Malignancies
Complementary and Alternative Medicine Among Patients With Hematologic Malignancies in France
Integrative medicine promotes the incorporation of elements from complementary and alternative medicines (CAM) into patient care.
- Trial name
- COMPLHEMATO (NCT07541326)
- Testing
- Questionnaire on Complementary and Alternative Medicines (CAM)
- Where
- 2 sites in France
- Volunteers
- 85 people
- Sponsor
- University Hospital, Limoges
Luspatercept, Poor Erythroid Engraftment
Luspatercept in Preventing Poor Erythroid Engraftment for Hematological Malignancies With Moderate to Severe Myelofibrosis
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important treatment for hematological malignancies. Poor erythroid engraftment after transplantation is a serious complication, especially in patients with…
- Conditions
- Luspatercept, Poor Erythroid Engraftment, Hematological Malignancies, Myelofibrosis (MF)
- Trial name
- NCT07539779
- Testing
- Luspatercept, Control
- Where
- China
- Volunteers
- 196 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hematological Malignancy, Neutropenia
Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia
Antibacterial prophylaxis is recommended in patients at high risk of infection, specifically patients undergoing acute leukemia induction therapy or hematopoietic stem cell transplant (HSCT) who are expected to have profound…
- Trial name
- NCT05537896
- Testing
- Eravacycline
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- West Virginia University